ADVERSE PERINATAL OUTCOME AND RESISTANT ENTEROBACTERIACEAE AFTER ANTIBIOTIC USAGE FOR PREMATURE RUPTURE OF THE MEMBRANES AND GROUP-B STREPTOCOCCUS CARRIAGE
Rs. Mcduffie et al., ADVERSE PERINATAL OUTCOME AND RESISTANT ENTEROBACTERIACEAE AFTER ANTIBIOTIC USAGE FOR PREMATURE RUPTURE OF THE MEMBRANES AND GROUP-B STREPTOCOCCUS CARRIAGE, Obstetrics and gynecology, 82(4), 1993, pp. 487-489
Objective: To report a case series of adverse perinatal outcomes assoc
iated with resistant Enterobacteriaceae after antibiotic usage for pre
mature rupture of the membranes (PROM) and group B streptococcus. Meth
ods: Maternal and neonatal records were reviewed of four cases in whic
h adverse perinatal outcomes occurred from resistant Enterobacteriacea
e after antibiotic usage for either PROM or positive group B streptoco
ccal cultures. Information on clinical setting, antibiotic usage, mate
rnal and neonatal complications, and maternal and neonatal cultures wa
s noted. Results: All four cases were complicated by PROM at 25-35 wee
ks' gestation. Ampicillin or amoxicillin was used in several clinical
settings, including therapeutically for the presence of group B strept
ococcus, presumptively for PROM, and prophylactically pending the resu
lts of group B streptococcal cultures. Clinical chorioamnionitis subse
quently developed in all four cases, and in two cases the maternal cou
rse was prolonged and complicated by persistent fever and the need for
therapy for pelvic vein thrombophlebitis. Two neonates died from fulm
inant clinical sepsis. A third infant, one of a twin gestation, was st
illborn, presumably because of sepsis. In three cases, neonatal and pl
acental cultures revealed Escherichia coli resistant to ampicillin; in
the fourth case, Klebsiella pneumoniae was identified, with only inte
rmediate sensitivity to ampicillin. Conclusion: Resistant Enterobacter
iaceae associated with adverse perinatal outcomes may result from the
use of antibiotics, such as ampicillin or amoxicillin, after PROM. In
deciding whether antibiotic therapy for PROM or group B streptococcal
prophylaxis is appropriate, the value of purported benefits must be we
ighed against presumably infrequent but serious outcomes, including ne
onatal sepsis and death due to selection or overgrowth of resistant or
ganisms.